首页 > 最新文献

Cochrane Evidence Synthesis and Methods最新文献

英文 中文
Development of the InSynQ checklist: A tool for planning and reporting the synthesis questions in systematic reviews of interventions 开发 InSynQ 核对表:规划和报告干预措施系统综述问题的工具
Pub Date : 2023-12-12 DOI: 10.1002/cesm.12036
Miranda S. Cumpston, Joanne E. McKenzie, Rebecca Ryan, Ella Flemyng, James Thomas, Sue E. Brennan

Introduction

Methods guidance and appraisal tools for systematic reviews require specification of the question and eligibility criteria for the review (“PICO for the review”). Less emphasis has been given to specifying the question and criteria for each synthesis (“PICO for each synthesis”), yet decisions about which studies to include in each synthesis can critically influence the utility and findings of a review. This paper describes the rationale and methods for developing the InSynQ (Intervention Synthesis Questions) tool for planning and reporting synthesis questions in reviews of interventions. The aim is to provide transparency about the basis of the tool and contribute to evidence on methods for developing guidance for research conduct and reporting.

Methods

Informed by EQUATOR Network methods, we (1) established a project group; (2) examined reporting of the “PICO for each synthesis” in published reviews; (3) reviewed existing reporting guidance and the Cochrane Handbook for Systematic Reviews of Interventions; (4) drafted items with elaboration, explanation, and examples; (5) conducted consultation meetings, an evaluation survey and pilot test; (6) incorporated feedback.

Results

Existing reporting guidelines do not distinguish the review and synthesis PICO, with limited coverage of the elements needed to specify the PICO for each synthesis. Using the PRISMA 2020 format, the draft tool contained 10 items with essential and additional reporting elements, explanations, and examples. Revisions arising from consultation meetings (>30 people), included adding an eleventh item on consumer and stakeholder involvement, a figure explaining PICO for each synthesis, and integrating examples into elements/explanations. All respondents to the survey (12 people) said the tool would help them plan or appraise synthesis questions. InSynQ is available at https://InSynQ.info.

Conclusion

Transparent reporting of the development process contributes to the evidence base for methods to develop guidance. It may improve uptake of InSynQ, in turn enhancing the clarity of syntheses.

导言 系统综述的方法指南和评估工具要求明确综述的问题和资格标准("综述的 PICO")。然而,关于在每项综述中纳入哪些研究的决定会对综述的效用和结果产生至关重要的影响。本文介绍了开发 InSynQ(干预综述问题)工具的原理和方法,该工具用于规划和报告干预综述中的综述问题。目的是使该工具的基础透明化,并为制定研究行为和报告指南的方法提供证据。 方法 我们借鉴了 EQUATOR 网络的方法,(1) 成立了一个项目组;(2) 检查了已发表综述中 "每项综述的 PICO "的报告情况;(3) 回顾了现有的报告指南和《干预措施系统性综述 Cochrane 手册》;(4) 起草了附有详细说明、解释和示例的项目;(5) 召开了咨询会议,进行了评估调查和试点测试;(6) 纳入了反馈意见。 结果 现有的报告指南没有区分综述和综述的 PICO,对说明每项综述的 PICO 所需的要素覆盖有限。使用 PRISMA 2020 格式,工具草案包含 10 个项目,包括基本和附加报告要素、解释和示例。根据咨询会议(30 人)的意见进行了修订,包括增加第 11 个关于消费者和利益相关者参与的项目、每个综述的 PICO 解释图,以及将示例整合到要素/解释中。调查的所有受访者(12 人)都表示该工具有助于他们规划或评估综合问题。InSynQ 可在 https://InSynQ.info 网站上查阅。 结论 透明的开发过程报告有助于为指南开发方法提供证据基础。它可以提高 InSynQ 的使用率,进而提高综述的清晰度。
{"title":"Development of the InSynQ checklist: A tool for planning and reporting the synthesis questions in systematic reviews of interventions","authors":"Miranda S. Cumpston,&nbsp;Joanne E. McKenzie,&nbsp;Rebecca Ryan,&nbsp;Ella Flemyng,&nbsp;James Thomas,&nbsp;Sue E. Brennan","doi":"10.1002/cesm.12036","DOIUrl":"https://doi.org/10.1002/cesm.12036","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Methods guidance and appraisal tools for systematic reviews require specification of the question and eligibility criteria for the review (“PICO for the review”). Less emphasis has been given to specifying the question and criteria for each synthesis (“PICO for each synthesis”), yet decisions about which studies to include in each synthesis can critically influence the utility and findings of a review. This paper describes the rationale and methods for developing the InSynQ (Intervention Synthesis Questions) tool for planning and reporting synthesis questions in reviews of interventions. The aim is to provide transparency about the basis of the tool and contribute to evidence on methods for developing guidance for research conduct and reporting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Informed by EQUATOR Network methods, we (1) established a project group; (2) examined reporting of the “PICO for each synthesis” in published reviews; (3) reviewed existing reporting guidance and the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>; (4) drafted items with elaboration, explanation, and examples; (5) conducted consultation meetings, an evaluation survey and pilot test; (6) incorporated feedback.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Existing reporting guidelines do not distinguish the review and synthesis PICO, with limited coverage of the elements needed to specify the PICO for each synthesis. Using the PRISMA 2020 format, the draft tool contained 10 items with essential and additional reporting elements, explanations, and examples. Revisions arising from consultation meetings (&gt;30 people), included adding an eleventh item on consumer and stakeholder involvement, a figure explaining PICO for each synthesis, and integrating examples into elements/explanations. All respondents to the survey (12 people) said the tool would help them plan or appraise synthesis questions. InSynQ is available at https://InSynQ.info.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Transparent reporting of the development process contributes to the evidence base for methods to develop guidance. It may improve uptake of InSynQ, in turn enhancing the clarity of syntheses.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"1 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138571044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ten tips for successful assessment of risk of bias in randomized trials using the RoB 2 tool: Early lessons from Cochrane 使用RoB 2工具成功评估随机试验偏倚风险的十个提示:来自Cochrane的早期经验
Pub Date : 2023-12-03 DOI: 10.1002/cesm.12031
Theresa H. M. Moore, Julian P. T. Higgins, Kerry Dwan

Introduction

RoB 2 is a tool used by systematic reviewers to assess risk of bias in randomized trials. Over a period of 19 months working as editors for Cochrane, we saw many instances where users of RoB 2 frequently applied the tool in ways the developers had not intended, despite availability of detailed guidance, webinars and FAQs.

Methods

In this paper we highlight the ten main issues that we observed, with the aims of optimising the application of the RoB 2 tool, avoiding some of the frequent misapplications of the tool.

Results

Issues noted included failure to state an effect of interest, applying the tool to an entire study rather than to a specific numerical result, omitting key signaling questions and relying on outdated views of causes of bias.

Conclusion

Such omissions and misapplications can lead to overly harsh or lenient assessments of bias with potential to change the confidence we have in an evidence base of randomized trials. We recommend that teams planning to use RoB 2 include at least one member familiar with the RoB 2 detailed guidance and that they use the free resources, such as webinars and FAQs, from the developers of RoB 2 and Cochrane. Our ten tips should be useful to non-Cochrane systematic reviewers as well as to peer reviewers and editors in Cochrane and other journals.

RoB 2是系统审稿人用来评估随机试验偏倚风险的工具。在作为Cochrane编辑的19个月里,我们看到很多例子,RoB 2的用户经常以开发者意想不到的方式使用该工具,尽管有详细的指导、网络研讨会和常见问题解答。在本文中,我们强调了我们观察到的十个主要问题,目的是优化罗布2工具的应用,避免工具的一些频繁误用。注意到的问题包括未能说明感兴趣的影响,将工具应用于整个研究而不是特定的数字结果,忽略关键的信号问题以及依赖于过时的偏见原因观点。这样的遗漏和误用可能导致过于苛刻或宽松的偏倚评估,有可能改变我们对随机试验证据基础的信心。我们建议计划使用RoB 2的团队包括至少一名熟悉RoB 2详细指导的成员,并且他们使用RoB 2和Cochrane开发人员提供的免费资源,例如网络研讨会和faq。我们的十条建议应该对非Cochrane系统审稿人以及Cochrane和其他期刊的同行审稿人和编辑有用。
{"title":"Ten tips for successful assessment of risk of bias in randomized trials using the RoB 2 tool: Early lessons from Cochrane","authors":"Theresa H. M. Moore,&nbsp;Julian P. T. Higgins,&nbsp;Kerry Dwan","doi":"10.1002/cesm.12031","DOIUrl":"https://doi.org/10.1002/cesm.12031","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>RoB 2 is a tool used by systematic reviewers to assess risk of bias in randomized trials. Over a period of 19 months working as editors for Cochrane, we saw many instances where users of RoB 2 frequently applied the tool in ways the developers had not intended, despite availability of detailed guidance, webinars and FAQs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this paper we highlight the ten main issues that we observed, with the aims of optimising the application of the RoB 2 tool, avoiding some of the frequent misapplications of the tool.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Issues noted included failure to state an effect of interest, applying the tool to an entire study rather than to a specific numerical result, omitting key signaling questions and relying on outdated views of causes of bias.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Such omissions and misapplications can lead to overly harsh or lenient assessments of bias with potential to change the confidence we have in an evidence base of randomized trials. We recommend that teams planning to use RoB 2 include at least one member familiar with the RoB 2 detailed guidance and that they use the free resources, such as webinars and FAQs, from the developers of RoB 2 and Cochrane. Our ten tips should be useful to non-Cochrane systematic reviewers as well as to peer reviewers and editors in Cochrane and other journals.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"1 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12031","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138480934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The international HTA database returned incomplete search results for NICE technology appraisals: An exploratory study and discussion of the implications 国际HTA数据库返回了NICE技术评估的不完整搜索结果:一项探索性研究和影响的讨论
Pub Date : 2023-12-01 DOI: 10.1002/cesm.12034
Christopher Cooper, Sabrina Smith

Introduction

The International Network of Agencies for Health Technology Assessment (INAHTA) database offers a single point of access for identifying technology appraisals, in contrast to searching multiple websites directly. The aim of this research is to compare the coverage of the INAHTA and Centre for Reviews and Dissemination (CRD) Health Technology Assessment (HTA) databases with direct searching on the National Institute for Health and Care Excellence (NICE) website to identify Technology Appraisals published by NICE.

Methods

NICE Technology Appraisals were downloaded from the NICE website (April 2022). Technology Appraisals were randomized and the first 20 Technology Appraisals constituted data for analysis. The INAHTA and CRD HTA databases were searched to determine if the 20 Technology Appraisals available on the NICE website were also available for retrieval.

Results

Coverage was incomplete. INAHTA: 15 of 20 Technology Appraisals (75%) were not identified via full title or intervention-specific searches. CRD HTA: 7 of 12 Technology Appraisals (58%) that were published before the last update of the database were not identified.

Conclusion

Findings indicate that researchers seeking to identify NICE Technology Appraisals should search the NICE website directly. How this finding impacts identification of guidance from other agencies should be evaluated.

国际卫生技术评估机构网络(INAHTA)数据库提供了识别技术评估的单一访问点,而不是直接搜索多个网站。本研究的目的是比较INAHTA和审查与传播中心(CRD)卫生技术评估(HTA)数据库的覆盖范围,以及直接搜索国家卫生与护理卓越研究所(NICE)网站以识别NICE发布的技术评估。方法从NICE网站(2022年4月)下载NICE技术评价。随机选取前20份技术评价作为分析数据。检索INAHTA和CRD HTA数据库,以确定NICE网站上提供的20项技术评估是否也可用于检索。结果覆盖不完整。INAHTA: 20个技术评价中有15个(75%)没有通过完整的标题或特定干预措施的搜索来确定。CRD HTA:在数据库最后一次更新之前发布的12项技术评估中有7项(58%)未被确定。研究结果表明,寻求NICE技术评价的研究人员应直接搜索NICE网站。应该评估这一发现对确定其他机构的指导有何影响。
{"title":"The international HTA database returned incomplete search results for NICE technology appraisals: An exploratory study and discussion of the implications","authors":"Christopher Cooper,&nbsp;Sabrina Smith","doi":"10.1002/cesm.12034","DOIUrl":"https://doi.org/10.1002/cesm.12034","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The International Network of Agencies for Health Technology Assessment (INAHTA) database offers a single point of access for identifying technology appraisals, in contrast to searching multiple websites directly. The aim of this research is to compare the coverage of the INAHTA and Centre for Reviews and Dissemination (CRD) Health Technology Assessment (HTA) databases with direct searching on the National Institute for Health and Care Excellence (NICE) website to identify Technology Appraisals published by NICE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>NICE Technology Appraisals were downloaded from the NICE website (April 2022). Technology Appraisals were randomized and the first 20 Technology Appraisals constituted data for analysis. The INAHTA and CRD HTA databases were searched to determine if the 20 Technology Appraisals available on the NICE website were also available for retrieval.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Coverage was incomplete. INAHTA: 15 of 20 Technology Appraisals (75%) were not identified via full title or intervention-specific searches. CRD HTA: 7 of 12 Technology Appraisals (58%) that were published before the last update of the database were not identified.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Findings indicate that researchers seeking to identify NICE Technology Appraisals should search the NICE website directly. How this finding impacts identification of guidance from other agencies should be evaluated.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"1 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138468522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stakeholder involvement in a Cochrane review of physical rehabilitation after stroke: Description and reflections 利益相关者参与卒中后身体康复的Cochrane综述:描述和反思
Pub Date : 2023-12-01 DOI: 10.1002/cesm.12032
Julie Brown, Gill Baer, Sheila Cameron, Karl Jackson, Carrol Lamouline, Richard Morley, Diane Ormsby, Anneliese Synnot, Alex Todhunter-Brown

Introduction

It is good practice to involve stakeholders in systematic reviews, but it is not clear how best to involve them.

Aim

To describe and reflect on the stakeholder involvement within an update of a Cochrane review of physical rehabilitation after stroke.

Methods

A stakeholder group, comprising 15 stroke survivors, carers, and physiotherapists from across the United Kingdom, were recruited and contributed throughout the process of the review. A framework was used to describe when and how stakeholders were involved. Stakeholders provided feedback on their involvement after meetings. An amended version of a validated patient engagement tool was used to collect reflections on the stakeholder involvement process.

Results

Five stakeholder meetings were held throughout the review process, supplemented by additional communication. Several changes were made to the review structure, analyses, and wording as a direct result of the stakeholder involvement. Stakeholders and researchers agreed that stakeholders' contributions were taken seriously and influenced the review. Stakeholders felt that they were given the chance to share their views and that information was shared well before, during, and after each meeting to help them to contribute knowledgeably in the process. Stakeholder reflections highlighted a number of key lessons relating to stakeholder involvement, including process of reflection and feedback, use of remote/virtual meetings, need for adequate time and funding, tensions experienced by clinicians, and recruitment considerations.

Conclusions

We describe and reflect on stakeholder involvement in a systematic review and explores practical ways to support meaningful engagement during systematic review production. Our experience supports the view that coproducing reviews with stakeholders can make systematic reviews more relevant and meaningful. Our approach and experiences can be used to inform future review coproduction, supporting development of useful reviews that will improve clinical practice.

让涉众参与系统评审是一个很好的实践,但是如何最好地让他们参与还不清楚。目的描述和反思卒中后肢体康复的Cochrane综述更新中利益相关者的参与。方法一个利益相关者小组,包括来自英国各地的15名中风幸存者、护理人员和物理治疗师,被招募并在整个审查过程中做出贡献。一个框架被用来描述涉众何时以及如何参与。利益相关者在会议结束后就其参与情况提供了反馈。使用经过验证的患者参与工具的修订版本来收集对利益相关者参与过程的反思。结果在整个评审过程中召开了五次利益相关者会议,并辅以额外的沟通。作为涉众参与的直接结果,对评审结构、分析和措辞进行了一些更改。利益相关者和研究人员一致认为,利益相关者的贡献得到了认真对待,并影响了评审。利益相关者认为他们有机会分享他们的观点,并且在每次会议之前,期间和之后都很好地分享了信息,以帮助他们在此过程中做出明智的贡献。利益相关者反思强调了与利益相关者参与相关的一些关键经验教训,包括反思和反馈过程、远程/虚拟会议的使用、对充足时间和资金的需求、临床医生所经历的紧张关系以及招聘考虑。我们描述并反思了利益相关者在系统评估中的参与,并探索了在系统评估生产过程中支持有意义的参与的实际方法。我们的经验支持这样一种观点,即与涉众共同进行评审可以使系统评审更加相关和有意义。我们的方法和经验可用于为未来的联合审查提供信息,支持开发有用的审查,以改善临床实践。
{"title":"Stakeholder involvement in a Cochrane review of physical rehabilitation after stroke: Description and reflections","authors":"Julie Brown,&nbsp;Gill Baer,&nbsp;Sheila Cameron,&nbsp;Karl Jackson,&nbsp;Carrol Lamouline,&nbsp;Richard Morley,&nbsp;Diane Ormsby,&nbsp;Anneliese Synnot,&nbsp;Alex Todhunter-Brown","doi":"10.1002/cesm.12032","DOIUrl":"https://doi.org/10.1002/cesm.12032","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>It is good practice to involve stakeholders in systematic reviews, but it is not clear how best to involve them.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To describe and reflect on the stakeholder involvement within an update of a Cochrane review of physical rehabilitation after stroke.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A stakeholder group, comprising 15 stroke survivors, carers, and physiotherapists from across the United Kingdom, were recruited and contributed throughout the process of the review. A framework was used to describe when and how stakeholders were involved. Stakeholders provided feedback on their involvement after meetings. An amended version of a validated patient engagement tool was used to collect reflections on the stakeholder involvement process.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Five stakeholder meetings were held throughout the review process, supplemented by additional communication. Several changes were made to the review structure, analyses, and wording as a direct result of the stakeholder involvement. Stakeholders and researchers agreed that stakeholders' contributions were taken seriously and influenced the review. Stakeholders felt that they were given the chance to share their views and that information was shared well before, during, and after each meeting to help them to contribute knowledgeably in the process. Stakeholder reflections highlighted a number of key lessons relating to stakeholder involvement, including process of reflection and feedback, use of remote/virtual meetings, need for adequate time and funding, tensions experienced by clinicians, and recruitment considerations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We describe and reflect on stakeholder involvement in a systematic review and explores practical ways to support meaningful engagement during systematic review production. Our experience supports the view that coproducing reviews with stakeholders can make systematic reviews more relevant and meaningful. Our approach and experiences can be used to inform future review coproduction, supporting development of useful reviews that will improve clinical practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"1 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138468526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of SARS-CoV-2 testing strategies: A scoping review SARS-CoV-2检测策略的有效性:范围审查
Pub Date : 2023-11-21 DOI: 10.1002/cesm.12030
KM Saif-Ur-Rahman, Ani Movsisyan, Kavita Kothari, Thomas Conway, Marie Tierney, Caoimhe Madden, Petek Eylul Taneri, Jane A. O'Halloran, Nadra Nurdin, Lena Murphy, Deirdre Mulholland, Andrea C. Tricco, Declan Devane

Introduction

Rapid identification of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infections by testing potentially reduced coronavirus disease-19 (COVID-19) cases. Testing strategies varied across countries and during different stages of the pandemic. This scoping review aims to map the available evidence on the effectiveness of SARS-CoV-2 testing strategies for suspected cases and asymptomatic populations to inform the development of World Health Organization recommendations for SARS-CoV-2 testing strategies.

Methods

We followed the standard methods for scoping reviews. We searched Medline (OVID), EMBASE (Elsevier), and Europe PMC using a comprehensive search strategy. The search was conducted in January 2023 and covered the period from January 2020 to January 2023. Two review authors independently screened the titles and abstracts, and full texts. Data were extracted onto a pilot-tested form by a review author and cross-checked by another review author. We provided a descriptive report summarizing the extracted data around the outcomes and created an interactive map of the available evidence using the evidence for policy and practice mapper.

Results

We identified 34,550 citations from the databases. After the screening, we included 17 studies from 11 countries for data extraction. The study designs were randomized controlled trials (n = 3), nonrandomized experimental studies (n = 3), cohort studies (n = 3), cross-sectional studies (n = 4), self-controlled case series (n = 1), and economic evaluations (n = 3).  Among the included studies, 14 used reverse transcription-polymerase chain reaction and 10 studies used antigen-detecting rapid diagnostic test. The settings of the studies were healthcare facilities (n = 8), communities (n = 4), schools, and workplaces (n = 3). Included studies considered symptomatic and asymptomatic individuals, or both, or asymptomatic contacts. Most of the studies (n = 14) reported the COVID-19 positivity rate as the primary outcome. Other reported outcomes are the number of COVID-19 cases (n = 11), number of hospitalizations and deaths (n = 3), and cost (n = 3).

Conclusion

We identified evidence gaps in the effectiveness of SARS-CoV-2 testing strategies, particularly in specific settings such as schools and long-term care facilities. This scoping review provides a foundati

通过检测可能减少的冠状病毒病-19 (COVID-19)病例,快速识别严重急性呼吸综合征-冠状病毒2 (SARS-CoV-2)感染。各国和大流行不同阶段的检测策略各不相同。本次范围审查的目的是绘制关于SARS-CoV-2检测策略对疑似病例和无症状人群有效性的现有证据,为世卫组织制定SARS-CoV-2检测策略建议提供信息。方法采用标准方法进行范围评价。我们使用综合搜索策略检索Medline (OVID)、EMBASE (Elsevier)和Europe PMC。该调查于2023年1月进行,涵盖时间为2020年1月至2023年1月。两位综述作者独立筛选了标题、摘要和全文。数据由一位综述作者提取到试点测试表格中,并由另一位综述作者进行交叉检查。我们提供了一份描述性报告,总结了围绕结果提取的数据,并使用政策和实践证据映射器创建了可用证据的交互式地图。结果我们从数据库中鉴定出34,550条引文。筛选后,我们纳入了来自11个国家的17项研究进行数据提取。研究设计为随机对照试验(n = 3)、非随机实验研究(n = 3)、队列研究(n = 3)、横断面研究(n = 4)、自我对照病例系列(n = 1)和经济评价(n = 3)。在纳入的研究中,14项研究采用逆转录聚合酶链反应,10项研究采用抗原检测快速诊断试验。研究的环境为医疗机构(n = 8)、社区(n = 4)、学校和工作场所(n = 3)。纳入的研究考虑了有症状和无症状的个体,或两者都有,或无症状接触者。大多数研究(n = 14)将COVID-19阳性率作为主要指标。报告的其他结局包括COVID-19病例数(n = 11)、住院和死亡人数(n = 3)以及费用(n = 3)。我们发现了SARS-CoV-2检测策略有效性方面的证据差距,特别是在学校和长期护理机构等特定环境中。这种范围审查为进一步的研究提供了基础,使研究人员和利益相关者能够集中精力解决已确定的差距。
{"title":"Effectiveness of SARS-CoV-2 testing strategies: A scoping review","authors":"KM Saif-Ur-Rahman,&nbsp;Ani Movsisyan,&nbsp;Kavita Kothari,&nbsp;Thomas Conway,&nbsp;Marie Tierney,&nbsp;Caoimhe Madden,&nbsp;Petek Eylul Taneri,&nbsp;Jane A. O'Halloran,&nbsp;Nadra Nurdin,&nbsp;Lena Murphy,&nbsp;Deirdre Mulholland,&nbsp;Andrea C. Tricco,&nbsp;Declan Devane","doi":"10.1002/cesm.12030","DOIUrl":"https://doi.org/10.1002/cesm.12030","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Rapid identification of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infections by testing potentially reduced coronavirus disease-19 (COVID-19) cases. Testing strategies varied across countries and during different stages of the pandemic. This scoping review aims to map the available evidence on the effectiveness of SARS-CoV-2 testing strategies for suspected cases and asymptomatic populations to inform the development of World Health Organization recommendations for SARS-CoV-2 testing strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We followed the standard methods for scoping reviews. We searched Medline (OVID), EMBASE (Elsevier), and Europe PMC using a comprehensive search strategy. The search was conducted in January 2023 and covered the period from January 2020 to January 2023. Two review authors independently screened the titles and abstracts, and full texts. Data were extracted onto a pilot-tested form by a review author and cross-checked by another review author. We provided a descriptive report summarizing the extracted data around the outcomes and created an interactive map of the available evidence using the evidence for policy and practice mapper.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified 34,550 citations from the databases. After the screening, we included 17 studies from 11 countries for data extraction. The study designs were randomized controlled trials (<i>n</i> = 3), nonrandomized experimental studies (<i>n</i> = 3), cohort studies (<i>n</i> = 3), cross-sectional studies (<i>n</i> = 4), self-controlled case series (<i>n</i> = 1), and economic evaluations (<i>n</i> = 3).  Among the included studies, 14 used reverse transcription-polymerase chain reaction and 10 studies used antigen-detecting rapid diagnostic test. The settings of the studies were healthcare facilities (<i>n</i> = 8), communities (<i>n</i> = 4), schools, and workplaces (<i>n</i> = 3). Included studies considered symptomatic and asymptomatic individuals, or both, or asymptomatic contacts. Most of the studies (<i>n</i> = 14) reported the COVID-19 positivity rate as the primary outcome. Other reported outcomes are the number of COVID-19 cases (<i>n</i> = 11), number of hospitalizations and deaths (<i>n</i> = 3), and cost (<i>n</i> = 3).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We identified evidence gaps in the effectiveness of SARS-CoV-2 testing strategies, particularly in specific settings such as schools and long-term care facilities. This scoping review provides a foundati","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"1 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12030","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138432116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Responsibilities for receiving and using individual participant data 接收和使用个人参与者数据的责任
Pub Date : 2023-11-03 DOI: 10.1002/cesm.12028
Kylie E. Hunter, Aidan C. Tan, Angela C. Webster, Daniel G. Hamilton, Adrian Barnett, Lee Jones, Myra Cheng, Salma Fahridin, Antonio Laguna-Camacho, Sol Libesman, Mark Hoffmann, Rui Wang, Anna Lene Seidler

Background

Sharing of individual participant data enhances the value of existing data to generate new evidence and inform decision-making. While there is strong in-principle support for data sharing, in practice study data are often difficult to find, access, and re-use. Currently, there is no consensus statement to guide the data-sharing process. In particular, more guidance is needed on the responsibilities of data recipients for re-using individual participant data.

Purpose

To determine views on the responsibilities of recipients of study data, and to propose how these responsibilities could be met.

Methods

A 2-h online focus group was conducted at the 2021 Association for Interdisciplinary Meta-research and Open Science conference. Three example data-sharing scenarios were discussed (evidence synthesis, study reproducibility, and secondary analyses). Notes and audio transcripts were collated using thematic analysis and shared with attendees for further iterative input.

Results

A purposive sample of 16 conference delegates attended the focus group. Analyses revealed four recurring themes that were synthesized into recommendations. The “privacy and ethics” theme described the need for data recipients to prioritize the protection of participant privacy, and the recommendation to proactively share a secure data management plan and evidence of ethical oversight with the data provider. The “capability and resourcing” theme required recipients to demonstrate sufficient capacity to process and analyze study data. The “recognition and collaboration” theme asserted the responsibility to acknowledge the contributions of data providers and invite them to contribute to the secondary project. Last, the “compliance” theme focused on the responsibility to adhere to local data sharing regulations.

Conclusions

Successful data sharing and re-use requires cooperation from multiple stakeholders. We identified the responsibilities of recipients of study data to the individual from whom data arose and the research team who collected the data. Implementation of these in practice could facilitate increased data sharing.

个人参与者数据的共享提高了现有数据的价值,以产生新的证据并为决策提供信息。虽然数据共享在原则上得到了强有力的支持,但在实践中,研究数据往往难以找到、访问和重用。目前,没有共识声明来指导数据共享过程。特别是,需要更多关于数据接收方在重用单个参与者数据方面的责任的指导。目的确定对研究数据接收者责任的看法,并提出如何履行这些责任的建议。方法在2021年跨学科元研究和开放科学协会会议上进行2小时的在线焦点小组讨论。讨论了三个示例数据共享场景(证据合成、研究可重复性和二次分析)。使用主题分析整理笔记和音频记录,并与与会者分享进一步的迭代输入。结果有目的的16名会议代表参加了焦点小组。分析揭示了四个反复出现的主题,这些主题被综合成建议。“隐私与道德”主题描述了数据接收方优先保护参与者隐私的必要性,以及主动与数据提供方共享安全数据管理计划和道德监督证据的建议。“能力和资源”主题要求接收方证明有足够的能力处理和分析研究数据。“认可与协作”主题强调了承认数据提供者的贡献并邀请他们为二级项目做出贡献的责任。最后,“合规”主题侧重于遵守当地数据共享法规的责任。成功的数据共享和重用需要多方利益相关者的合作。我们确定了研究数据接收者对数据来源的个人和收集数据的研究团队的责任。在实践中实施这些措施可以促进更多的数据共享。
{"title":"Responsibilities for receiving and using individual participant data","authors":"Kylie E. Hunter,&nbsp;Aidan C. Tan,&nbsp;Angela C. Webster,&nbsp;Daniel G. Hamilton,&nbsp;Adrian Barnett,&nbsp;Lee Jones,&nbsp;Myra Cheng,&nbsp;Salma Fahridin,&nbsp;Antonio Laguna-Camacho,&nbsp;Sol Libesman,&nbsp;Mark Hoffmann,&nbsp;Rui Wang,&nbsp;Anna Lene Seidler","doi":"10.1002/cesm.12028","DOIUrl":"10.1002/cesm.12028","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Sharing of individual participant data enhances the value of existing data to generate new evidence and inform decision-making. While there is strong in-principle support for data sharing, in practice study data are often difficult to find, access, and re-use. Currently, there is no consensus statement to guide the data-sharing process. In particular, more guidance is needed on the responsibilities of data recipients for re-using individual participant data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To determine views on the responsibilities of recipients of study data, and to propose how these responsibilities could be met.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A 2-h online focus group was conducted at the 2021 Association for Interdisciplinary Meta-research and Open Science conference. Three example data-sharing scenarios were discussed (evidence synthesis, study reproducibility, and secondary analyses). Notes and audio transcripts were collated using thematic analysis and shared with attendees for further iterative input.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A purposive sample of 16 conference delegates attended the focus group. Analyses revealed four recurring themes that were synthesized into recommendations. The “privacy and ethics” theme described the need for data recipients to prioritize the protection of participant privacy, and the recommendation to proactively share a secure data management plan and evidence of ethical oversight with the data provider. The “capability and resourcing” theme required recipients to demonstrate sufficient capacity to process and analyze study data. The “recognition and collaboration” theme asserted the responsibility to acknowledge the contributions of data providers and invite them to contribute to the secondary project. Last, the “compliance” theme focused on the responsibility to adhere to local data sharing regulations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Successful data sharing and re-use requires cooperation from multiple stakeholders. We identified the responsibilities of recipients of study data to the individual from whom data arose and the research team who collected the data. Implementation of these in practice could facilitate increased data sharing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"1 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135411363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical excision methods for skin cancer involving the nail unit: A systematic review 皮肤癌症涉及指甲单位的手术切除方法:系统综述
Pub Date : 2023-10-16 DOI: 10.1002/cesm.12026
Claire M. Hardie, Ryckie G. Wade, Justin C. R. Wormald, Brian Stafford, Faye Elliott, Julia Newton-Bishop, Donald Dewar

Introduction

Skin cancer affecting the nail unit is rare but is associated with morbidity, and melanoma has a high mortality rate. The principal treatment is surgical excision and methods can be classified into digit-sparing surgery or amputation. Digit-sparing surgery (wide excision or Mohs surgery) may be safe and effective for malignancies involving the nail unit in comparison to amputation if there is not bony invasion. The objective was to assess the efficacy and safety of different methods of surgical excision for skin cancer involving the nail unit.

Methods

Prospective comparative studies (randomized controlled studies, non-randomized controlled studies and prospective observational studies) of surgical excision for skin cancer of the nail unit in all participants were eligible for inclusion. We searched electronic databases, trials registers and conference abstracts. We checked the reference lists of included studies and related systematic reviews for further references to relevant studies, and we contacted experts to enquire if they were aware of any additional relevant trials. We used standard methodological procedures expected by Cochrane. The primary outcomes were overall survival, disease free survival and adverse events/outcomes at 30 days. The secondary outcomes were quality of life outcomes. We planned to use GRADE to assess the quality of the evidence for each outcome.

Results

We did not identify any studies that met the inclusion criteria for this review. We have been unable to assess our outcomes of overall survival, disease free survival, adverse events/effects and quality of life.

Conclusions

As we have not identified any studies for inclusion, we are unable to assess the efficacy and safety of different methods of surgical excision for skin cancer involving the nail unit. We suggest that comprehensive cancer registry analysis is required in this field to obtain meaningful data.

简介影响指甲单位的皮肤癌症很罕见,但与发病率有关,黑色素瘤死亡率很高。主要的治疗方法是手术切除,方法可分为保留手指手术或截肢。如果没有骨侵犯,与截肢相比,保留手指手术(大面积切除或Mohs手术)对涉及指甲单元的恶性肿瘤可能是安全有效的。目的是评估不同方法的皮肤癌症手术切除涉及指甲单位的有效性和安全性。方法对所有受试者进行指甲部皮肤癌症手术切除的前瞻性比较研究(随机对照研究、非随机对照研究和前瞻性观察性研究)。我们搜索了电子数据库、试验登记册和会议摘要。我们检查了纳入研究的参考文献列表和相关系统综述,以获取对相关研究的进一步参考,并联系了专家,询问他们是否知道任何其他相关试验。我们使用了Cochrane期望的标准方法学程序。主要结果是总生存率、无疾病生存率和30天的不良事件/结果。次要结果是生活质量结果。我们计划使用GRADE来评估每个结果的证据质量。结果我们没有发现任何符合本综述纳入标准的研究。我们无法评估我们的总体生存率、无疾病生存率、不良事件/影响和生活质量的结果。结论由于我们尚未确定任何可纳入的研究,我们无法评估涉及指甲单元的皮肤癌症不同手术切除方法的有效性和安全性。我们建议在这一领域需要进行全面的癌症登记分析,以获得有意义的数据。
{"title":"Surgical excision methods for skin cancer involving the nail unit: A systematic review","authors":"Claire M. Hardie,&nbsp;Ryckie G. Wade,&nbsp;Justin C. R. Wormald,&nbsp;Brian Stafford,&nbsp;Faye Elliott,&nbsp;Julia Newton-Bishop,&nbsp;Donald Dewar","doi":"10.1002/cesm.12026","DOIUrl":"https://doi.org/10.1002/cesm.12026","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Skin cancer affecting the nail unit is rare but is associated with morbidity, and melanoma has a high mortality rate. The principal treatment is surgical excision and methods can be classified into digit-sparing surgery or amputation. Digit-sparing surgery (wide excision or Mohs surgery) may be safe and effective for malignancies involving the nail unit in comparison to amputation if there is not bony invasion. The objective was to assess the efficacy and safety of different methods of surgical excision for skin cancer involving the nail unit.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Prospective comparative studies (randomized controlled studies, non-randomized controlled studies and prospective observational studies) of surgical excision for skin cancer of the nail unit in all participants were eligible for inclusion. We searched electronic databases, trials registers and conference abstracts. We checked the reference lists of included studies and related systematic reviews for further references to relevant studies, and we contacted experts to enquire if they were aware of any additional relevant trials. We used standard methodological procedures expected by Cochrane. The primary outcomes were overall survival, disease free survival and adverse events/outcomes at 30 days. The secondary outcomes were quality of life outcomes. We planned to use GRADE to assess the quality of the evidence for each outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We did not identify any studies that met the inclusion criteria for this review. We have been unable to assess our outcomes of overall survival, disease free survival, adverse events/effects and quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>As we have not identified any studies for inclusion, we are unable to assess the efficacy and safety of different methods of surgical excision for skin cancer involving the nail unit. We suggest that comprehensive cancer registry analysis is required in this field to obtain meaningful data.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"1 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50135556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cluster-randomized controlled trials: A tutorial 集群随机对照试验:教程
Pub Date : 2023-09-05 DOI: 10.1002/cesm.12024
Marty Chaplin, Kerry Dwan

This tutorial focuses on cluster-randomized controlled trials (cluster-RCTs). We will explain what cluster-RCTs are, why they might be used, and how to include data from cluster-RCTs in systematic reviews.

What is a cluster-randomized controlled trial?

In most RCTs, individuals are randomly assigned to intervention groups. In a cluster-RCT, groups of individuals (e.g., schools, communities, or clinics) are randomized to intervention groups.

Why use a cluster-randomized controlled trial design?

Table 1 outlines reasons that a cluster-RCT design might be used by researchers, and provides an example for each of these reasons.

How do I perform risk of bias assessments for cluster-randomized controlled trials?

An adaptation of the Risk of Bias 2 tool [1] outlines issues that should be considered when assessing the risk of bias of cluster-RCTs. Detailed guidance on the use of the adapted tool is also available [2].

What is a “unit-of analysis” error?

Individuals from the same cluster are likely to respond in a similar way to each other, and therefore observations made for these individuals cannot be assumed to be independent. It is important that this dependency is accounted for when analyzing data from a cluster-RCT.

If the effects of clustering are ignored, and the analysis is conducted as if individuals were randomized, a “unit-of-analysis error” occurs [3], as the unit of analysis (the individual) is different to the unit of randomization (the cluster). When a “unit-of-analysis error” occurs, confidence intervals for the effect estimate will be artificially narrow and associated p-values will be artificially small. The trial will also have too much weight in any meta-analysis. Incorrect conclusions may therefore be drawn from the results of the cluster-RCT itself, and any meta-analyses that include the cluster-RCT.

How do I include data from a cluster-randomized controlled trial in a systematic review?

When a cluster-RCT is included in a systematic review (with or without a meta-analysis), it is important that the effect estimate and its corresponding confidence interval are adjusted for the clustered nature of the data.

The ideal approach is to extract cluster-adjusted effect estimates and a measure of uncertainty (i.e., confidence interval or standard error) that have been calculated by the trial authors using statistical methods such as multilevel models or generalized estimating equations. These effect estimates and the measure of uncertainty may be included in meta-analyses that use the generic inverse variance method.

Another acceptable approach is to conduct the analysis at the cluster level. The data set for analysis would include a summary measurement for each cluster, and the sample size is the number of clusters. These data can then be treated as if they were from an RCT that ra

本教程的重点是集群随机对照试验(集群随机对照实验)。我们将解释什么是集群随机对照试验,为什么可能使用它们,以及如何在系统综述中包括集群随机对照研究的数据。什么是整群随机对照试验?在大多数随机对照试验中,个体被随机分配到干预组。在集群随机对照试验中,将个体组(如学校、社区或诊所)随机分为干预组。为什么要使用整群随机对照试验设计?表1概述了研究人员可能使用集群随机对照试验设计的原因,并为每一个原因提供了一个例子。我如何对集群随机对照试验进行偏倚风险评估?对偏倚风险2工具[1]的改编概述了评估集群随机对照试验偏倚风险时应考虑的问题。还提供了关于使用自适应工具的详细指南[2]。什么是“分析单位”错误?来自同一集群的个体可能会以相似的方式做出反应,因此不能假设对这些个体的观察是独立的。重要的是,在分析聚类-RCT的数据时要考虑到这种依赖性。如果忽略聚类的影响,并且分析是像对个体进行随机化一样进行的,则会出现“分析误差单位”[3],因为分析单位(个体)与随机化单位(聚类)不同。当出现“分析误差单位”时,效应估计的置信区间将被人为地缩小,相关的p值将被人为缩小。该试验在任何荟萃分析中也会有太大的分量。因此,从整群随机对照试验本身的结果以及包括整群-RCT在内的任何荟萃分析中都可能得出错误的结论。我如何在系统综述中纳入整群随机控制试验的数据?当聚类随机对照试验被纳入系统综述(有或没有荟萃分析)时,重要的是要根据数据的聚类性质调整效应估计及其相应的置信区间。理想的方法是提取聚类调整后的效应估计和不确定性度量(即置信区间或标准误差),这些不确定性度量是试验作者使用统计方法(如多级模型或广义估计方程)计算的。这些影响估计和不确定性度量可以包括在使用通用逆方差方法的荟萃分析中。另一种可以接受的方法是在集群一级进行分析。用于分析的数据集将包括每个聚类的汇总测量,样本量是聚类的数量。然后可以将这些数据视为来自随机对照试验的数据,该随机对照试验对个体进行随机化(个体随机对照试验);标准公式可用于获得效应估计和置信区间,如果合适,数据也可纳入荟萃分析。这种方法的局限性在于,聚类RCT的样本大小(以及因此的精度和功率)可能会大大降低。这种方法包括计算试验中每一组的有效样本量。有效样本量可以定义为单个随机对照试验具有与聚类随机对照试验相同的能力和精度所需的样本量[4]。ICC是衡量同一聚类内个体在特定结果方面相似性的指标[5],通常很小。ICC可以在审判出版物中报告,也可以通过与审判作者的联系获得。试验的两个阶段的设计效果通常是相同的。对于二分结果,在试验的每一组中经历该事件的个体数量也应除以相同的设计效果。对于连续结果,均值和标准差应保持不变。如果评审作者的效应估计和标准误差没有针对聚类进行调整,则可以将标准误差乘以设计效应的平方根(如上所述),以获得解释聚类效应的标准误差。标准误差可以根据置信区间计算,反之亦然,如Cochrane手册[6]第6.3章所述。然后,可以将效应估计和调整后的标准误差或置信区间包括在使用通用逆方差方法的元分析中。常见问题如果没有报告国际刑事法院怎么办?如果审判出版物或与审判作者的联系中没有国际刑事法院,则可以从类似的审判中借用国际刑事法院。如果借用或估计了ICC,则可以进行敏感性分析,以调查在合理限度内改变ICC对分析结果的影响。 如果无法获得集群调整后的效果估计,该怎么办?如果使用这些方法中的任何一种都无法获得经聚类调整的效果估计,并且综述作者希望在文本、表格或荟萃分析中提供未经调整的效果评估,则需要强调的是,由于缺乏聚类调整,效果估计的置信区间可能太窄。如果综述作者在荟萃分析中确实包括了来自聚类随机对照试验的未调整效果估计,则应进行敏感性分析,以探讨将这些未调整效果评估从荟萃分析中排除的影响。将未经调整的影响估计完全排除在荟萃分析之外也是完全合理的。我可以在同一荟萃分析中包括集群随机对照试验和个体随机对照试验吗?理论上是的。按随机化单位(即集群或个体)进行分层或亚组分析,以调查个体随机对照试验和集群随机对照试验之间的干预效果是否不同,这可能会提供信息。例如,在疫苗试验中,如果给一个村庄内的所有人接种疫苗,而不是只给一些人接种,疫苗可能会更有效。进一步阅读和在线内容关于集群随机对照试验的更多信息,可以在《Cochrane干预措施系统评价手册》[6]的第23.1章中找到。Cochrane Training制作了一个关于如何调整集群随机对照试验数据的微观学习模块,以配合本文[7](图1)。Bland教授和Kerry博士在《英国医学杂志》[8-11]上发表的多篇论文中更详细地讨论了集群随机对照实验。Marty Chaplin:概念化;书写——原始草稿;写作——复习和编辑。Kerry Dwan:概念化;监督;写作——复习和编辑。提交人声明没有利益冲突。
{"title":"Cluster-randomized controlled trials: A tutorial","authors":"Marty Chaplin,&nbsp;Kerry Dwan","doi":"10.1002/cesm.12024","DOIUrl":"https://doi.org/10.1002/cesm.12024","url":null,"abstract":"<p>This tutorial focuses on cluster-randomized controlled trials (cluster-RCTs). We will explain what cluster-RCTs are, why they might be used, and how to include data from cluster-RCTs in systematic reviews.</p><p><b>What is a cluster-randomized controlled trial?</b></p><p>In most RCTs, individuals are randomly assigned to intervention groups. In a cluster-RCT, groups of individuals (e.g., schools, communities, or clinics) are randomized to intervention groups.</p><p><b>Why use a cluster-randomized controlled trial design?</b></p><p>Table 1 outlines reasons that a cluster-RCT design might be used by researchers, and provides an example for each of these reasons.</p><p><b>How do I perform risk of bias assessments for cluster-randomized controlled trials?</b></p><p>An adaptation of the Risk of Bias 2 tool [<span>1</span>] outlines issues that should be considered when assessing the risk of bias of cluster-RCTs. Detailed guidance on the use of the adapted tool is also available [<span>2</span>].</p><p><b>What is a “unit-of analysis” error?</b></p><p>Individuals from the same cluster are likely to respond in a similar way to each other, and therefore observations made for these individuals cannot be assumed to be independent. It is important that this dependency is accounted for when analyzing data from a cluster-RCT.</p><p>If the effects of clustering are ignored, and the analysis is conducted as if individuals were randomized, a “unit-of-analysis error” occurs [<span>3</span>], as the unit of analysis (the individual) is different to the unit of randomization (the cluster). When a “unit-of-analysis error” occurs, confidence intervals for the effect estimate will be artificially narrow and associated <i>p</i>-values will be artificially small. The trial will also have too much weight in any meta-analysis. Incorrect conclusions may therefore be drawn from the results of the cluster-RCT itself, and any meta-analyses that include the cluster-RCT.</p><p><b>How do I include data from a cluster-randomized controlled trial in a systematic review?</b></p><p>When a cluster-RCT is included in a systematic review (with or without a meta-analysis), it is important that the effect estimate and its corresponding confidence interval are adjusted for the clustered nature of the data.</p><p>The ideal approach is to extract cluster-adjusted effect estimates and a measure of uncertainty (i.e., confidence interval or standard error) that have been calculated by the trial authors using statistical methods such as multilevel models or generalized estimating equations. These effect estimates and the measure of uncertainty may be included in meta-analyses that use the generic inverse variance method.</p><p>Another acceptable approach is to conduct the analysis at the cluster level. The data set for analysis would include a summary measurement for each cluster, and the sample size is the number of clusters. These data can then be treated as if they were from an RCT that ra","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"1 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50121946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What tool do undergraduate pharmacy students prefer when grading systematic review evidence: AMSTAR-2 or ROBIS? 药学本科生在对系统审查证据进行评分时更喜欢什么工具:AMSTAR-2还是ROBIS?
Pub Date : 2023-08-09 DOI: 10.1002/cesm.12023
Shaun W. H. Lee

Introduction

While systematic reviews (SRs) are considered the highest form of evidence in the hierarchy, the quality and standard of reviews varies. Two quality assessment tools have been developed to assess the variation in such standards. This study compared the preference, validity, reliability, and applicability of using A Measurement Tool to Assess Systematic Reviews (AMSTAR-2) and the Risk of Bias in Systematic Reviews (ROBIS) for critically appraising evidence by pharmacy students.

Materials and Methods

Students attended eight lectures on evidence-based medicine. Students independently assessed two SRs using AMSTAR-2 and ROBIS. The agreement between both tools were calculated using Spearman's test while interrater reliability was calculated using Fleiss' κ statistics.

Results

Students reported a preference for the AMSTAR-2 tool due to its clear and distinct rating criteria as well as guidance provided by the tool's developer. In comparison, students found the items on the ROBIS tool difficult to judge as it was subjective. A moderate agreement between both tools on the overall domain ratings was noted (Spearman rs = 0.60). There was slight agreement in the overall confidence using AMSTAR-2 (κ = 0.05; 95% confidence interval [CI]: 0.01–0.12) and the overall domain in ROBIS (κ = 0.09; 95% CI: 0.01–0.16).

Conclusion

The AMSTAR-2 tool had a low level of concordance in ratings of review among students. However, the AMSTAR-2 tool was preferred by students due to the clear guidance and ease of use.

引言虽然系统审查被认为是层次结构中的最高证据形式,但审查的质量和标准各不相同。已经开发了两个质量评估工具来评估这些标准的差异。本研究比较了使用评估系统评价的测量工具(AMSTAR-2)和系统评价中的偏倚风险(ROBIS)对药学学生批判性评价证据的偏好、有效性、可靠性和适用性。材料与方法学生参加了八场循证医学讲座。学生使用AMSTAR-2和ROBIS独立评估了两个SR。使用Spearman检验计算两种工具之间的一致性,而使用Fleissκ统计计算参与者间的可靠性。结果学生们报告说,他们更喜欢AMSTAR-2工具,因为它有明确而独特的评级标准以及工具开发人员提供的指导。相比之下,学生们发现ROBIS工具上的项目很难判断,因为它是主观的。两种工具在总体域名评级方面达成了适度一致(Spearman rs = 0.60)。使用AMSTAR-2(κ = 0.05;95%置信区间[CI]:0.01–0.12)和ROBIS中的整体域(κ = 0.09;95%可信区间:0.01–0.16)。结论AMSTAR-2工具在学生复习评分中的一致性水平较低。然而,AMSTAR-2工具由于其清晰的指导和易用性而受到学生的青睐。
{"title":"What tool do undergraduate pharmacy students prefer when grading systematic review evidence: AMSTAR-2 or ROBIS?","authors":"Shaun W. H. Lee","doi":"10.1002/cesm.12023","DOIUrl":"https://doi.org/10.1002/cesm.12023","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>While systematic reviews (SRs) are considered the highest form of evidence in the hierarchy, the quality and standard of reviews varies. Two quality assessment tools have been developed to assess the variation in such standards. This study compared the preference, validity, reliability, and applicability of using A Measurement Tool to Assess Systematic Reviews (AMSTAR-2) and the Risk of Bias in Systematic Reviews (ROBIS) for critically appraising evidence by pharmacy students.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Students attended eight lectures on evidence-based medicine. Students independently assessed two SRs using AMSTAR-2 and ROBIS. The agreement between both tools were calculated using Spearman's test while interrater reliability was calculated using Fleiss' <i>κ</i> statistics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Students reported a preference for the AMSTAR-2 tool due to its clear and distinct rating criteria as well as guidance provided by the tool's developer. In comparison, students found the items on the ROBIS tool difficult to judge as it was subjective. A moderate agreement between both tools on the overall domain ratings was noted (Spearman <i>r</i><sub>s</sub> = 0.60). There was slight agreement in the overall confidence using AMSTAR-2 (<i>κ</i> = 0.05; 95% confidence interval [CI]: 0.01–0.12) and the overall domain in ROBIS (<i>κ</i> = 0.09; 95% CI: 0.01–0.16).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The AMSTAR-2 tool had a low level of concordance in ratings of review among students. However, the AMSTAR-2 tool was preferred by students due to the clear guidance and ease of use.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"1 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50125499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring dichotomous outcomes using risk ratios, odds ratios, and the risk difference: A tutorial 使用风险比、比值比和风险差异测量二分结果:教程
Pub Date : 2023-07-24 DOI: 10.1002/cesm.12022
Rachel Richardson, Kerry Dwan, Afroditi Kanellopoulou

In this article, we look at risk ratios (RR), odds ratios (OR), and the risk difference (RD); what they are, how to interpret them, and when they should be used.

The RR, the OR, and the RD are used to compare the occurrence of an event in two groups for dichotomous outcomes. For example, a recent Cochrane review compared oral misoprostol to placebo for induction of labour and reported whether the women in each group went on to have a caesarian section, or not [1].

The RR provides a measure of how much higher or lower the risk of the event happening in the intervention group is, compared to the risk of the same event happening in the control group. Risk might sound like a complicated term but it is actually just the probability of an event happening.

Example: Trial A is interested in whether patients were readmitted to hospital within 30 days of an operation (procedure X) and compared this with patients who had a different operation (procedure Y). One hundred out of 200 patients who had procedure X were readmitted within 30 days. The risk (or probability) of this event occurring is 100 divided by 200, or 0.5. One hundred and fifty patients out of 200 patients who had procedure Y were readmitted within 30 days. The risk (or probability) of this event occurring is 150 divided by 200 or 0.75.

This means that if patients have procedure X, their risk of being readmitted is reduced by 33% compared to their risk if they had procedure Y. We can also express this as a probability—the probability of them being readmitted is reduced by 33%.

On the other hand, if 140 out of 200 patients who had procedure X (risk: 140/200 = 0.7) and 120 of 200 patients who had procedure Y (risk: 120/200 = 0.6) were readmitted within 30 days, then the RR equals 0.7/0.6 = 1.17. This means that if patients have procedure X, their risk of being readmitted is increased by 17% compared to their risk if they have procedure Y. When the risk in the intervention group is the same as the risk in the control group, the RR will be 1, and we can say that the risks are the same for both groups.

The OR provides a measure of how much higher or lower the odds of the event happening in the intervention group are compared to the odds of the same event happening in the control group. Odds may also sound like a complicated term, but it merely refers to the probability of something happening compared to the probability of it not happening. If the odds of a horse winning the Kentucky Derby are 7 to 2 against, this means that over nine races it would be predicted to win twice and lose seven times.

Example: Let's go back to our hypothetical example of procedure X versus procedure Y. If 100 out of 200 patients who had procedure X were readmitted within 30 days, the odds of readmission would be 100/100 or 1. In betting terminology, this would be “evens”: the chances of being readmitted and not being readmitted are the same. If

在这篇文章中,我们研究了风险比(RR)、比值比(OR)和风险差(RD);它们是什么,如何解释它们,以及何时应该使用它们。RR、OR和RD用于比较两组中事件的发生情况,以获得二分结果。例如,最近的一项Cochrane综述将口服米索前列醇与安慰剂进行了引产比较,并报告了每组女性是否继续剖腹产[1]。RR提供了一种衡量干预组发生该事件的风险比对照组发生相同事件的风险高或低的指标。风险听起来可能是一个复杂的术语,但实际上它只是一个事件发生的概率。示例:试验A感兴趣的是患者是否在手术后30天内再次入院(程序X),并将其与接受不同手术的患者(程序Y)进行比较。200名接受X手术的患者中有100人在30天内再次入院。该事件发生的风险(或概率)为100除以200,即0.5。在200名接受Y手术的患者中,150名患者在30天内再次入院。这种事件发生的风险(或概率)是150除以200或0.75。这意味着,如果患者接受X手术,他们再次入院的风险比接受Y手术的风险降低了33%,如果200名接受X手术的患者中有140人(风险:140/200 = 0.7)和200名接受Y手术的患者中的120名(风险:120/200 = 0.6)在30天内再次入院,则RR等于0.7/0.6 = 1.17.这意味着,如果患者进行X手术,与进行Y手术的风险相比,他们再次入院的风险增加了17%。当干预组的风险与对照组的风险相同时,RR将为1,我们可以说两组的风险都相同。OR提供了干预组中发生事件的几率比对照组中发生相同事件的几率高多少或低多少的度量。几率听起来可能也是一个复杂的术语,但它只是指某件事发生的概率与不发生的概率。如果一匹马在肯塔基德比中获胜的几率是7比2,这意味着在九场比赛中,预计它会赢两次,输七次。示例:让我们回到X程序与Y程序的假设示例。如果200名接受X程序的患者中有100人在30天内再次入院,则再次入院的几率为100/100或1。在博彩术语中,这将是“偶数”:被重新接纳和不被重新接纳的机会是相同的。如果200名接受Y手术的患者中有150人再次入院,则再次入院的几率为150/50,即3比1。这意味着与Y手术相比,X手术后再次入院的概率降低。接受X手术的患者再次入院与未再次入院的机会相同,而四分之三的接受Y手术患者将再次入院。在第二种情况下,如果140/200手术X名患者(几率:140/60 = 2.3)和120/200手术Y患者(比值:120/80 = 1.5)在30天内再次入院,则OR等于2.3/1.5 = 1.6.与RR一样,如果干预组的几率与对照组的几率相同,OR将为1,可以说两组的几率都相同。RD是一个绝对值,而不是一个比值,告诉我们两组中发生事件的概率之间的差异。在上述第一种情况下,X组再次入院的风险为100/200或0.5。手术Y组的风险为150/200或0.75。RD为0.5–0.75,等于−0.25。这意味着,与Y程序相比,每100人中,X程序将减少25人再次入院。风险和OR等效果估计是根据从整个人群样本中获得的数据计算得出的。这意味着我们不能确定我们的估计是真值:置信区间(CI)给了我们一个“误差幅度”。例如,0.67的RR,95%的CI在0.57到0.78之间,这意味着(广义上)我们可以95%地确定真实效应估计介于这两个值之间。也可以计算不同值的CI,例如90%或99%。正如我们从上面的例子中看到的,RR和or产生的效果估计可能会因计算方式的不同而显著不同。当事件很少发生时,风险和几率似乎相似。然而,当事件发生得更频繁时,几率似乎与风险大不相同。这些差异影响RR和OR的计算。 回到前面的例子:如果接受X和Y手术的人再次入院的风险很低(例如,X手术组200人中有15人,Y手术组200个人中有10人,则RR为0.075/0.05 = 1.5.相同情况下的OR为0.08/0.05 = 1.6然而,如果再次入院的风险要高得多(例如,X手术组有150人,Y手术组有100人),则RR为0.75/0.5 = 1.5,而OR为3/1 = 3.0.OR可以产生比RR更多的“极值”。如果OR被解释为RR,这可能会导致误解。因此,在系统评价中,使用RR作为首选效果指标通常会更好。然而,OR的属性可以使它们从统计的角度更容易处理。我们经常看到,与RR的荟萃分析相比,包括OR在内的荟萃分析具有更高的异质性。然而,作者永远不应该依赖异质性的大小来选择哪种类型的估计最有效。RD在计算选择一种干预而不是另一种干预的“现实世界”含义时可能会有所帮助。例如,与程序Y相比,程序X可能防止每100名患者中有25人再次入院,这一知识可以帮助临床医生决定实施哪种程序。评审员的关键是预先指定将使用的措施,并正确处理和解释他们选择的效果措施类型。关于计算和使用风险和OR的更多信息,以及其他二分结果可以在《Cochrane干预措施系统评价手册》[2]的第6.4章中找到。Cochrane Training在本文中制作了一个关于测量二分结果的微学习模块[3]。Bland教授和Altman教授在他们的Statistics Notes系列中更详细地讨论了OR的性质,发表于英国医学杂志[4]。Rachel Richardson:概念化;方法论项目管理;书写——原始草稿;写作——复习和编辑。Kerry Dwan:概念化;写作——复习和编辑。Afroditi Kanellopoulou:概念化;书写——原始草稿。
{"title":"Measuring dichotomous outcomes using risk ratios, odds ratios, and the risk difference: A tutorial","authors":"Rachel Richardson,&nbsp;Kerry Dwan,&nbsp;Afroditi Kanellopoulou","doi":"10.1002/cesm.12022","DOIUrl":"https://doi.org/10.1002/cesm.12022","url":null,"abstract":"<p>In this article, we look at risk ratios (RR), odds ratios (OR), and the risk difference (RD); what they are, how to interpret them, and when they should be used.</p><p>The RR, the OR, and the RD are used to compare the occurrence of an event in two groups for dichotomous outcomes. For example, a recent Cochrane review compared oral misoprostol to placebo for induction of labour and reported whether the women in each group went on to have a caesarian section, or not [<span>1</span>].</p><p>The RR provides a measure of how much higher or lower the risk of the event happening in the intervention group is, compared to the risk of the same event happening in the control group. Risk might sound like a complicated term but it is actually just the probability of an event happening.</p><p>Example: Trial A is interested in whether patients were readmitted to hospital within 30 days of an operation (procedure X) and compared this with patients who had a different operation (procedure Y). One hundred out of 200 patients who had procedure X were readmitted within 30 days. The risk (or probability) of this event occurring is 100 divided by 200, or 0.5. One hundred and fifty patients out of 200 patients who had procedure Y were readmitted within 30 days. The risk (or probability) of this event occurring is 150 divided by 200 or 0.75.</p><p>This means that if patients have procedure X, their risk of being readmitted is <b>reduced</b> by 33% compared to their risk if they had procedure Y. We can also express this as a probability—the probability of them being readmitted is reduced by 33%.</p><p>On the other hand, if 140 out of 200 patients who had procedure X (risk: 140/200 = 0.7) and 120 of 200 patients who had procedure Y (risk: 120/200 = 0.6) were readmitted within 30 days, then the RR equals 0.7/0.6 = 1.17. This means that if patients have procedure X, their risk of being readmitted is <b>increased</b> by 17% compared to their risk if they have procedure Y. When the risk in the intervention group is the same as the risk in the control group, the RR will be 1, and we can say that the risks are the same for both groups.</p><p>The OR provides a measure of how much higher or lower the odds of the event happening in the intervention group are compared to the odds of the same event happening in the control group. Odds may also sound like a complicated term, but it merely refers to the probability of something happening compared to the probability of it not happening. If the odds of a horse winning the Kentucky Derby are 7 to 2 against, this means that over nine races it would be predicted to win twice and lose seven times.</p><p><i>Example</i>: Let's go back to our hypothetical example of procedure X versus procedure Y. If 100 out of 200 patients who had procedure X were readmitted within 30 days, the odds of readmission would be 100/100 or 1. In betting terminology, this would be “evens”: the chances of being readmitted and not being readmitted are the same. If","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"1 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50143136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cochrane Evidence Synthesis and Methods
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1